Urinary Tract and Gynecologic Malignancies

Česká verzia

Authors: J. Špaček jr. ¹; J. Petera ²; M. Broďák ¹; I. Práznovec ³; J. Špaček ³
Authors place of work: Urologická klinika LF UK a FN Hradec Králové ¹; Klinika onkologie a radioterapie LF UK a FN Hradec Králové ²; Porodnická a gynekologická klinika LF UK a FN Hradec Králové ³
Published in the journal: Klin Onkol 2018; 31(6): 414-420
Category: Review
doi: https://doi.org/10.14735/amko2018414

Summary

Background:

The close anatomical relationship of the urogenital system is a significant, and sometimes limiting, factor in oncogynecology. Reducing adverse effects (treatment-associated toxicity) is an integral part of cancer treatment. Radical surgery, as well as oncological therapy, which represent milestones in the treatment of such malignancies, may require tailoring the extension of the intervention in order to preserve other non-gynecological structures. Despite the progress in minimally invasive surgery, and evolution of radiotherapy and systemic therapy, treatment-related complications remain; indeed, their increasing prevalence in women raises questions about quality of life.

Aim:

Here, we highlight the modalities used to treat gynecological cancer and discuss the most common urological adverse effects related to these interventions. Knowledge of side effects, as well as methods of prevention, is fundamental if we are to preserve quality of life.

Conclusion:

reatment of gynecological cancer is based on cooperation between members of the multidisciplinary team. From this point-of-view, combination of two radical modalities (mainly surgery and radiotherapy) remains problematic. However, the patient’s prognosis, and plans for other possible oncological therapies, play an essential role in management of urological adverse effects related to cancer treatment.

Key words:

gynecologic neoplasms – complication – urinary tract – quality of life

This work was supported by project PROGES Q40.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 27. 9. 2018

Accepted: 21. 10. 2018

Zdroje

1. Záleský M, Zachoval R, Vik V et al. Urologické konsekvence gynekologických operací. Urol List 2008; 6(1): 78– 84.

2. Feranec R, Mouková L, Chovanec J. Prekancerózy v gynekologii – endometrium. Klin Onkol 2013; 26(Suppl.): S52– S53.

3. Ouldamer L, Fichet-Djavadian S, Marret H et al. Upper margin of para-aortic lymphadenectomy in cervical cancer. Acta Obstet Gynecol Scand 2012; 91(8): 893– 900. doi: 10.1111/ j.1600-0412.2012.01443.x.

4. Cibula D, Petruželka L et al. Onkogynekologie. Praha: Grada 2009.

5. Fader AN, Weise RM, Sinno AK et al. Utilization of minimally invasive surgery in endometrial cancer care: a quality and cost disparity. Obstet Gynecol 2016; 127(1): 91– 100. doi: 10.1097/ AOG.0000000000001180.

6. Casarin J, Multinu F, Ubl DS et al. Adoption of minimally invasive surgery and decrease in surgical morbidity for endometrial cancer treatment in the United States. Obstet Gynecol 2018; 131(2): 304– 311. doi: 10.1097/ AOG.0000000000002428.

7. Mendivil AA, Abaid LN, Brown JV 3rd et al. The safety and feasibility of minimally invasive sentinel lymph node staging using indocyanine green in the management of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2018; 224: 29– 32. doi: 10.1016/ j.ejogrb.2018.02.027.

8. Wu HH, Yang PY, Yeh GP et al. The detection of ureteral injuries after hysterectomy. J Minim Invasive Gynecol 2006; 13(5): 403– 408. doi: 10.1016/ j.jmig.2006.04.018.

9. El Abd AS, El-Abd SA, El-Enen MA et al. Immediate and late management of iatrogenic ureteric injuries: 28 years of experience. Arab J Urol 2015; 13(4): 250– 257. doi: 10.1016/ j.aju.2015.07.004.

10. Brodak M, Spacek J, Pacovsky J et al. Multidisciplinary approach as the optimum for surgical treatment of retroperitoneal sarcomas in women. Eur J Gynaecol Oncol 2013; 34(3): 234– 237.

11. Jarabák J, Zachoval R, Visokai V et al. Výskyt a řešení urologických komplikací po totální pánevní exenteraci provedené pro pokročilé nádory malé pánve. Ces Urol 2016; 20(1): 39– 47.

12. Loran OB, Veliev EL, Seregin AV et al. Quality of life in women after anterior pelvic exenteration. Urologiia 2016(2): 58– 62.

13. Speicher PJ, Goldsmith ZG, Nussbaum DP et al. Ureteral stenting in laparoscopic colorectal surgery. J Surg Res 2014; 190(1): 98– 103. doi: 10.1016/ j.jss.2014.02.025.

14. Brandes S, Coburn M, Armenakas N et al. Diagnosis and management of ureteric injury: an evidence-based analysis. BJU Int 2004; 94(3): 277– 289. doi: 10.1111/ j.1464-410X.2004.04978.x.

15. Chou MT, Wang CJ, Lien RC. Prophylactic ureteral catheterization in gynecologic surgery: a 12-year randomized trial in a community hospital. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20(6): 689– 693. doi: 10.1007/ s00192-008-0788-3.

16. Parpala-Spårman T, Paananen I, Santala M et al. Increasing numbers of ureteric injuries after the introduction of laparoscopic surgery. Scand J Urol Nephrol 2008; 42(5): 422– 427. doi: 10.1080/ 00365590802025857.

17. Visco AG, Taber KH, Weidner AC et al. Cost-effectiveness of universal cystoscopy to identify ureteral injury at hysterectomy. Obstet Gynecol 2001; 97(5 Pt 1): 685– 692.

18. Viswanathan AN, Lee LJ, Eswara JR et al. Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer 2014; 120(24): 3870– 3883. doi: 10.1002/ cncr.28849.

19. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31(5): 1341– 1346. doi: 10.1016/ 0360-3016(95)00060-C.

20. Cancer Therapy Evaluation Program. Bethesda: National Cancer Institute. [online]. Available from: https:/ / ctep.cancer.gov/ .

21. Čoupková I, Čoupek P, Krupa P. Komplikace spojené s radioterapií karcinomu prostaty, jejich prevence a léčba. Urol praxi 2011; 12(5): 292– 294.

22. Kubeš J, Vítek P, Dědečková K et al. Velmi pozdní následky radioterapie – limitující faktor současných radioterapeutických technik. Klin Onkol 2014; 27(3): 161–165. doi: 10.14735/amko2014161.

23. Chaturvedi AK, Engels EA, Gilbert ES et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007; 99(21): 1634– 1643. doi: 10.1093/ jnci/ djm201.

24. Gay HA, Barthold HJ, O’Meara E et al. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys 2012; 83(3): e353– e362. doi: 10.1016/ j.ijrobp.2012.01.023.

25. Šlampa P et al. Radiační onkologie v praxi. 3. vyd. Brno: Masarykův onkologický ústav 2011.

26. Nout RA, Putter H, Jürgenliemk-Schulz IM et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012; 48(11): 1638– 1648. doi: 10.1016/ j.ejca.2011.11.014.

27. de Boer SM, Powell ME, Mileshkin L et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19(3): 295– 309. doi: 10.1016/ S1470-2045(18)30079-2.

28. Nguyen TV, Petereit DG. High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer. Gynecol Oncol 1998; 71(2): 196– 203. doi: 10.1006/ gyno.1998.5148.

29. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334(1): 1– 6. doi: 10.1056/ NEJM199601043340101.

30. Song Y, Fei X, Song Y. Percutaneous nephrostomy versus indwelling ureteral stent in the management of gynecological malignancies. Int J Gynecol Cancer 2012; 22(4): 697– 702. doi: 10.1097/ IGC.0b013e318243b475.

31. Heyns CF. Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder. World J Urol 2012; 30(1): 77– 83. doi: 10.1007/ s00345-011-0725-9.

32. Emmert C, Rassler J, Köhler U. Survival and quality of life after percutaneous nephrostomy for malignant ureteric obstruction in patients with terminal cervical cancer. Arch Gynecol Obstet 1997; 259(3): 147– 151.

33. Ilhan O, Koç H, Akan H et al. Hemorrhagic cystitis as a complication of bone marrow transplantation. J Chemother 1997; 9(1): 56–61. doi: 10.1179/joc.1997.9.1.56.

34. Gandhi J, Chen A, Dagur G et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016; 215(6): 704– 711. doi: 10.1016/ j.ajog.2016.07.045.

35. Donát J. Klinické aspekty klimaktéria a postmenopauzy. Praha: Avicenum 1987.

36. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med 2005; 2 (Suppl. 3): 154– 165. doi: 10.1111/ j.1743-6109.2005.00131.x.